Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
These programs are especially helpful for uninsured or low-income individuals: Manufacturer Programs Novo Nordisk, the maker of Ozempic and Wegovy, has assistance programs for eligible patients
Patients can access these therapies immediately without insurance authorization delays
Patent Expiry Outlook and Market Implications The upcoming patent expirations for key semaglutide products Ozempic, Rybelsus, and Wegovy between 2026 and 2032, present both strategic challenges and opportunities for market stakeholders
But GLP-1s should drive both numbers downand the effect applies to both people with and without diabetes
US$ 26.59
US$ 28.43
US$ 29.14
US$ 24.39
